ARTICLE | Clinical News
Skeletal Targeted Radiotherapy: Phase I/II data; Phase II
May 30, 2000 7:00 AM UTC
In NERX’s Phase I/II trial, 18 of 40 evaluable patients had complete remissions (absence of the M-protein myeloma marker), without increased serious toxicity. Patients were treated with high-dose or c...